Price additional FDA approval to support the efficacy of RA treatment ACTEMRA in Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration has extended the Actemra (tocilizumab, RoActemra in the EU) about the inhibition and slow structural joint damage, improvement in physical function, and implementation of major [...]